A retrospective study compared the efficacy of enzalutamide and abiraterone acetate in men with metastatic castration-resistant prostate cancer. Men treated with enzalutamide lived about a month longer, had longer time to next treatment switching, and time to PSA response compared to those who received abiraterone acetate. Enzalutamide showed small but statistically significant improvements in outcomes, particularly in overall survival, time to next treatment switching or death, and time to PSA response. While limitations in the study were acknowledged, the findings may help guide treatment decisions for men with metastatic castration-resistant prostate cancer.
Source link
Enzalutamide confers small benefit vs. abiraterone in metastatic prostate cancer
